Skip to Main Content

Thomas Lab

Viral Hepatitis and Hepatocellular Carcinoma

Contact Us

Investigator / Contact Person Emmanuel Thomas


The mission of Dr. Thomas's program is to develop integrated, multidisciplinary approaches to the study of liver cancer/liver diseases and to bridge clinical medicine and basic science with translation of fundamental knowledge to prevention, diagnosis, and treatment of liver diseases.

Since completing a Doris Duke Clinical Fellowship and graduating from the University of Miami Miller School of Medicine in May 2007 simultaneously obtaining both the MD and PhD degrees, Dr. Thomas has made steady progress toward creating and implementing a translational research program focused on preventing liver disease and hepatocellular carcinoma. Our program leverages resources and clinical/scientific expertise available through the Miami CTSI, the Schiff Center for Liver Diseases, the Sylvester Comprehensive Cancer Center and the Miami Center for AIDS Research to address the rapid development of liver disease and Hepatocellular Carcinoma which occurs in patients with viral hepatitis. Infection by the Hepatitis B and C viruses and HIV impacts our South Florida community significantly and our efforts will help minimize their detrimental effects in our catchment area.

Having been raised in Miami-Dade county, Dr. Thomas has a strong commitment to improving the health of our local community. Recently, breakthroughs have been achieved in the treatment of viral hepatitis and specifically for treatment of HCV. Potent all oral therapies are now available to cure patients with HCV infection. Through our community screening program, we are identifying HCV infected individuals and linking them to care so that they can be cured of this deadly virus. In addition, we are also facilitating the ability of uninsured patients to receive these costly medications through patient assistance programs.

Dr. Thomas' multidisciplinary research program in liver disease and HCC  is funded by the NIH through a five-year, renewable Outstanding Investigator Award (R35) from NIGMS on chronic viral infections in the liver.  In addition from NIGMS on chronic viral infections in the liver.  In addition, he has a five-year Bankhead-Coley Clinical Cancer Research Grant for the early identification of patients with liver disease that are most at risk to develop HCC.  Both of these grants are funded until 2022.